All In Biotech

Drug Trial Radar · NCT07729852

Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France

Open-Label Extension Study to Provide Access to ATH434 in Patients With Multiple System Atrophy

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

7

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Jul 2029

Study completion Jul 2029

Sponsor

Lead sponsor
Alterity TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.

Conditions

  • Multiple System Atrophy

Interventions

  • ATH434Drug

    ATH434 75 mg tablets administered orally twice daily (BID).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, Severity, and Relationship of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline to completion of study treatment, an average of 1 year.
  2. Change From Baseline in Clinical Laboratory ParametersTime frame: Baseline to completion of study treatment, an average of 1 year.
  3. Change From Baseline in Vital SignsTime frame: Baseline to completion of study treatment, an average of 1 year.
  4. Duration of Exposure to ATH434Time frame: Baseline to completion of study treatment, an average of 1 year.
  5. Cumulative Dose of ATH434Time frame: Baseline to completion of study treatment, an average of 1 year.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpital Universitaire Pitié Salpêtrière

    Paris, Île-de-France Region, France

  • Hôpital Pierre-Paul Riquet

    Toulouse, Midi-Pyrenees, France

  • Centre Hospitalier Universitaire de Bordeaux

    Bordeaux, New Aquitaine, France

  • Hôpital de la Timone

    Marseille, Provence-Alpes-Côte d'Azur Region, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.